USP drug classification [BR:br08302]
Ophthalmic Agents
Ophthalmic Anti-allergy Agents
Antihistamine and Mast Cell Stabilizer
Bepotastine
D01654 Bepotastine besylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
44 Allergic agents
449 Miscellaneous
4490 Miscellaneous
D01654 Bepotastine besylate (USAN); Bepotastine besilate (JP18)
Risk category of Japanese OTC drugs [BR:br08312]
First-class OTC drugs
Inorganic and organic chemicals
Bepotastine
D01654 Bepotastine besylate (USAN)
Drug groups [BR:br08330]
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG01327 Bepotastine
D01654 Bepotastine besylate
Dermatological agent
DG03243 Atopic dermatitis agent
D01654 Bepotastine besylate
Drug classes [BR:br08332]
Anti-allergic agent
DG01482 Histamine receptor H1 antagonist
D01654 Bepotastine besylate
Dermatological agent
DG03243 Atopic dermatitis agent
D01654 Bepotastine besylate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
HRH1
D01654 Bepotastine besylate (USAN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01654 Bepotastine besilate
D01654 Bepotastine besylate tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01654
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01654
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01654
Rx-to-OTC switch list in Japan [br08314.html]
D01654
Drug groups [BR:br08330]
Anti-allergic agent
DG01557 Histamine receptor antagonist
DG01482 Histamine receptor H1 antagonist
DG01327 Bepotastine